Wendy Stock to Biomarkers, Tumor
This is a "connection" page, showing publications Wendy Stock has written about Biomarkers, Tumor.
Connection Strength
0.653
-
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat Med. 2020 12; 26(12):1852-1858.
Score: 0.102
-
Biology and Treatment Paradigms in T Cell Acute Lymphoblastic Leukemia in Older Adolescents and Adults. Curr Treat Options Oncol. 2020 05 28; 21(7):57.
Score: 0.100
-
Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician. Clin Lymphoma Myeloma Leuk. 2018 10; 18(10):636-647.
Score: 0.087
-
Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leuk Lymphoma. 2016 10; 57(10):2298-306.
Score: 0.074
-
Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma. Leukemia. 2015 Oct; 29(10):2113-6.
Score: 0.069
-
Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1209-16.
Score: 0.045
-
Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia. Nat Genet. 2024 Nov; 56(11):2434-2446.
Score: 0.034
-
Studies of minimal residual disease in acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2000 Dec; 14(6):1289-305, viii-ix.
Score: 0.026
-
New Approaches to Treating Challenging Subtypes of ALL in AYA Patients. Curr Hematol Malig Rep. 2020 12; 15(6):424-435.
Score: 0.026
-
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Adv. 2019 12 23; 3(24):4228-4237.
Score: 0.024
-
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. N Engl J Med. 2016 11 24; 375(21):2023-2036.
Score: 0.020
-
Minimal residual disease in acute myeloid leukemia--current status and future perspectives. Curr Hematol Malig Rep. 2015 Jun; 10(2):132-44.
Score: 0.018
-
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Br J Haematol. 2014 May; 165(4):497-503.
Score: 0.016
-
NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies. Biol Blood Marrow Transplant. 2010 Oct; 16(10):1325-46.
Score: 0.013